Elizabeth Griffiths, MD
Hematology & Oncology · Buffalo, NYNPI 1962577171
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $104,304 of the $117,425 with a category attached, or 88.8%. 10 manufacturers reported payments, led by AstraZeneca at 29.6% of the total. Reporting peaked in 2024 at $28,120 and has fallen 86.6% since, to $3,760 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $1107.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$35K
- Bristol Myers Squibb$23K
- AbbVie$17K
- Taiho Oncology, Inc.$12K
- Apellis Pharmaceuticals, Inc.$11K
- Servier Pharmaceuticals LLC$7K
- plus $12K from 4 others
Across 197 payments — averaging $13,737 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$1.7M
- Blueprint Medicines Corporation$542K
- Taiho Oncology, Inc.$353K
- National Marrow Donor Program$37K
- Sanofi US Services Inc.$20K
- AstraZeneca$19K
- plus $8K from 3 others
What the payments were for
- Consulting fees$104,30489%
- Speaking & faculty fees$3,6973%
- Travel & lodging$6,9796%
- Food & beverage$2,4062%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $34,782 |
| Bristol Myers Squibb | 12 | $22,623 |
| AbbVie | 34 | $16,988 |
| Taiho Oncology, Inc. | 14 | $12,416 |
| Apellis Pharmaceuticals, Inc. | 3 | $10,697 |
| Servier Pharmaceuticals LLC | 10 | $7,495 |
| Novartis | 5 | $5,385 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,630 |
| Genentech USA, Inc. | 2 | $3,300 |
| Astellas Pharma US Inc | 1 | $110 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,425 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 32 | $1,803,277 |
| JakafiRuxolitinib Phosphate | 56 | $877,679 |
| OjjaaraMomelotinib Dihydrochloride | 33 | $865,711 |
| TibsovoIvosidenib | 18 | $571,284 |
| PromactaEltrombopag Olamine | 12 | $368,615 |
| InqoviDecitabine/Cedazuridine | 42 | $331,913 |
| InrebicFedratinib Dihydrochloride | 12 | $321,760 |
| ScemblixAsciminib Hydrochloride | 13 | $195,788 |
| Deferasirox | 12 | $72,029 |
| VenclextaVenetoclax | 16 | $42,266 |
| Imatinib Mesylate | 14 | $40,914 |
| Hydroxyurea | 40 | $1,018 |
| ValacyclovirValacyclovir Hcl | 13 | $308 |
| Duloxetine Hcl | 13 | $125 |
| Prednisone | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Servier Pharmaceuticals LLCTibsovo | $7,495 | $571,28418 claims |
| NovartisPromacta, Scemblix | $5,385 | $564,40325 claims |
| Taiho Oncology, Inc.Inqovi | $12,416 | $331,91342 claims |
| Bristol Myers SquibbInrebic | $22,623 | $321,76012 claims |
| AbbVieVenclexta | $16,988 | $42,26616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Buffalo
- Eunice WangBuffalo$295K
- Grace DyBuffalo$135K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.